SCHEMBL4115461

SCHEMBL4115461

COc1ccc2c3c(n(CC(=O)C(C)(C)C)c2c1)CCCC3=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.52
KDM4E B2RXH2 3/20 0.52
MAPK1 P28482 1/20 0.52
HTT P42858 1/20 0.52
HSD17B10 Q99714 1/20 0.52
PTGDR2 Q9Y5Y4 1/20 0.42
TSHR P16473 1/20 0.39
PKM P14618 2/20 0.39
CSNK2A2 P19784 2/20 0.39
CSNK2B P67870 2/20 0.39
CSNK2A1 P68400 2/20 0.39
ABCG2 Q9UNQ0 2/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
ALOX15 P16050 1/20 0.39
CYP2C19 P33261 1/20 0.39
HDAC1 Q13547 2/20 0.38
HDAC6 Q9UBN7 2/20 0.38
CNR2 P34972 1/20 0.38
DYRK1A Q13627 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3988515 0.88 KDM4E (0.55) ALDH1A1KDM4EMAPK1HTTHSD17B10
SCHEMBL3992329 0.85 HSD17B10 (0.49) ALDH1A1KDM4EMAPK1HTTHSD17B10
SCHEMBL14191560 0.84 ALDH1A1 (0.54) ALDH1A1KDM4EMAPK1HTTHSD17B10
SCHEMBL4108716 0.82 KDM4E (0.54) ALDH1A1KDM4EMAPK1HTTHSD17B10
SCHEMBL4119258 0.81 KDM4E (0.46) ALDH1A1KDM4EMAPK1HTTHSD17B10
SCHEMBL3994092 0.81 KDM4E (0.46) ALDH1A1KDM4EMAPK1HTTHSD17B10
SCHEMBL4096879 0.81 KDM4E (0.50) ALDH1A1KDM4EMAPK1HTTHSD17B10
SCHEMBL4107299 0.80 KDM4E (0.47) ALDH1A1KDM4EMAPK1HTTHSD17B10
SCHEMBL3988858 0.79 KDM4E (0.48) ALDH1A1KDM4EMAPK1HTTHSD17B10
SCHEMBL4109394 0.78 KDM4E (0.48) ALDH1A1KDM4EMAPK1HTTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1802300-A4 OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION MERCK & CO INC (US) 2009-05-27 EP disclosed
US-20080097108-A1 Ophthalmic Compositions for Treating Ocular Hypertension MERCK SHARP & DOHME CORP. 2008-04-24 US disclosed
US-20080097108-A1 Ophthalmic Compositions for Treating Ocular Hypertension MERCK SHARP & DOHME CORP. 2008-04-24 US disclosed
US-20080097108-A1 Ophthalmic Compositions for Treating Ocular Hypertension MERCK SHARP & DOHME CORP. 2008-04-24 US disclosed
EP-1802300-A1 OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION Merck & Co., Inc. (US) 2007-07-04 EP disclosed
WO-2006044232-A1 OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION MERCK & CO., INC. (US) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080097108-A1 Ophthalmic Compositions for Treating Ocular Hypertension KCNH2, KCNN1, KCNH3 ALDH1A1 979/4885KDM4E 1326/4885MAPK1 512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.